Literature DB >> 16622794

Development of small molecules designed to modulate protein-protein interactions.

Ye Che1, Bernard R Brooks, Garland R Marshall.   

Abstract

Protein-protein interactions are ubiquitous, essential to almost all known biological processes, and offer attractive opportunities for therapeutic intervention. Developing small molecules that modulate protein-protein interactions is challenging, owing to the large size of protein-complex interface, the lack of well-defined binding pockets, etc. We describe a general approach based on the "privileged-structure hypothesis" [Che, Ph.D. Thesis, Washington University, 2003] - that any organic templates capable of mimicking surfaces of protein-recognition motifs are potential privileged scaffolds as protein-complex antagonists--to address the challenges inherent in the discovery of small-molecule inhibitors of protein-protein interactions.

Mesh:

Substances:

Year:  2006        PMID: 16622794     DOI: 10.1007/s10822-006-9040-8

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  107 in total

1.  Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

Authors:  W H Miller; D P Alberts; P K Bhatnagar; W E Bondinell; J F Callahan; R R Calvo; R D Cousins; K F Erhard; D A Heerding; R M Keenan; C Kwon; P J Manley; K A Newlander; S T Ross; J M Samanen; I N Uzinskas; J W Venslavsky; C C Yuan; R C Haltiwanger; M Gowen; S M Hwang; I E James; M W Lark; D J Rieman; G B Stroup; L M Azzarano; K L Salyers; B R Smith; K W Ward; K O Johanson; W F Huffman
Journal:  J Med Chem       Date:  2000-01-13       Impact factor: 7.446

Review 2.  Protein-protein interfaces: mimics and inhibitors.

Authors:  A G Cochran
Journal:  Curr Opin Chem Biol       Date:  2001-12       Impact factor: 8.822

3.  The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC.

Authors:  D R Madden; J C Gorga; J L Strominger; D C Wiley
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

Review 4.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

Review 5.  Themes in RNA-protein recognition.

Authors:  D E Draper
Journal:  J Mol Biol       Date:  1999-10-22       Impact factor: 5.469

6.  Topological side-chain classification of beta-turns: ideal motifs for peptidomimetic development.

Authors:  Tran Trung Tran; Jim McKie; Wim D F Meutermans; Gregory T Bourne; Peter R Andrews; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2005-11-23       Impact factor: 3.686

7.  Synthesis, conformational properties, and antibody recognition of peptides containing beta-turn mimetics based on alpha-alkylproline derivatives.

Authors:  M G Hinds; J H Welsh; D M Brennand; J Fisher; M J Glennie; N G Richards; D L Turner; J A Robinson
Journal:  J Med Chem       Date:  1991-06       Impact factor: 7.446

8.  From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus.

Authors:  B K Blackburn; A Lee; M Baier; B Kohl; A G Olivero; R Matamoros; K D Robarge; R S McDowell
Journal:  J Med Chem       Date:  1997-02-28       Impact factor: 7.446

9.  The GYF domain is a novel structural fold that is involved in lymphoid signaling through proline-rich sequences.

Authors:  C Freund; V Dötsch; K Nishizawa; E L Reinherz; G Wagner
Journal:  Nat Struct Biol       Date:  1999-07

Review 10.  The stereochemistry of peptides containing alpha-aminoisobutyric acid.

Authors:  B V Prasad; P Balaram
Journal:  CRC Crit Rev Biochem       Date:  1984
View more
  17 in total

1.  Universal peptidomimetics.

Authors:  Eunhwa Ko; Jing Liu; Lisa M Perez; Genliang Lu; Amber Schaefer; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2010-12-23       Impact factor: 15.419

2.  Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction.

Authors:  Emilio Margolles-Clark; Oliver Umland; Norma S Kenyon; Camillo Ricordi; Peter Buchwald
Journal:  J Mol Med (Berl)       Date:  2009-08-26       Impact factor: 4.599

3.  The SCHOOL of nature: I. Transmembrane signaling.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-01

4.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

5.  Protein-protein interactions: making drug design second nature.

Authors:  Dan L Sackett; David Sept
Journal:  Nat Chem       Date:  2009-11       Impact factor: 24.427

6.  Correlations between secondary structure- and protein-protein interface-mimicry: the interface mimicry hypothesis.

Authors:  Jaru Taechalertpaisarn; Rui-Liang Lyu; Maritess Arancillo; Chen-Ming Lin; Lisa M Perez; Thomas R Ioerger; Kevin Burgess
Journal:  Org Biomol Chem       Date:  2019-03-20       Impact factor: 3.876

Review 7.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

8.  Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

Authors:  Landon R Whitby; Yoshio Ando; Vincent Setola; Peter K Vogt; Bryan L Roth; Dale L Boger
Journal:  J Am Chem Soc       Date:  2011-06-15       Impact factor: 15.419

Review 9.  TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

Authors:  Yun Song; Peter Buchwald
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

10.  Multicomponent assembly and diversification of novel heterocyclic scaffolds derived from 2-arylpiperidines.

Authors:  Simon Hardy; Stephen F Martin
Journal:  Org Lett       Date:  2011-05-20       Impact factor: 6.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.